Regulatory June 11, 2021 The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key employees
Regulatory June 11, 2021 Share subscriptions based on Nanoform Finland Plc’s multiple Stock Option Programs
Regulatory May 20, 2021 Cynthia Schwalm transitions to Senior Advisor Business Development US, from her role as member of the Board of Directors
Non Regulatory May 18, 2021 Nanoform’s final clinical results confirm value proposition to the pharma industry
Regulatory May 11, 2021 The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key employees
Regulatory April 7, 2021 Share subscriptions based on Nanoform Finland Plc’s multiple Stock Option Programs
Regulatory April 6, 2021 Resolutions of the Constitutive Meeting of the Board of Directors of Nanoform Finland Plc
Regulatory April 6, 2021 Resolutions of Nanoform Finland Plc’s Annual General Meeting on April 6, 2021
Non Regulatory March 31, 2021 Nanoform and Nacuity Pharmaceuticals Sign Technology Proof of Concept (“PoC”) Agreement for Two Ophthalmic Drug Candidates
Non Regulatory March 22, 2021 Nanoform launches next-generation STARMAP® v2.0, the AI-based drug candidate selection tool for CESS®
Regulatory March 10, 2021 Nanoform Finland Plc: 5 633 803 new shares registered with the trade register
Regulatory March 9, 2021 Nanoform Finland Plc successfully completes new share issue raising EUR 40 million
Regulatory March 9, 2021 Nanoform Finland Plc announces its intention to carry out a new share issue to raise approximately EUR 40 million
Non Regulatory February 12, 2021 Invitation to presentation of Nanoform’s year-end report for 2020 on February 26, 2021
Non Regulatory January 11, 2021 Finnish Foundation for Share Promotion and Nasdaq Helsinki has chosen Nanoform as the company of the month (article in Finnish)
Non Regulatory December 23, 2020 Nanoform included in Nasdaq First North 25 index as of Jan 4th, 2021
Regulatory December 17, 2020 Nanoform and Herantis partner to look for opportunities to enhance BBB penetration of CDNF and xCDNF molecules
Non Regulatory December 8, 2020 Notification of major shareholdings according to Nanoform’s Articles of Association
Regulatory November 27, 2020 Nanoform Finland Plc, Interim Report January – September 2020, November 27[th], 2020 at 08:00 a.m. Finnish time
Regulatory November 27, 2020 Nanoform launches technology for biologics and sets new near-term business target for 2021
Regulatory October 23, 2020 The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key employees
Regulatory October 20, 2020 Nanoform initiates GMP campaign for first-in-human trial of nanoformed drug by year end – ahead of schedule
Regulatory September 2, 2020 Share subscriptions based on Nanoform Finland Plc’s 2/2019 and 1/2020 Stock Option Programs
Regulatory September 1, 2020 Resolutions of Nanoform Finland Plc’s Extraordinary General Meeting and Board of Directors on September 1, 2020
Regulatory August 28, 2020 NANOFORM FINLAND PLC, 2020 HALF YEAR FINANCIAL REPORT, 28 AUGUST 2020 AT 8:10 AM EEST
Regulatory June 25, 2020 The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key employees
Regulatory June 10, 2020 Exercise of over-allotment option in relation to the initial public offering of Nanoform Finland Plc and termination of the stabilization period
Regulatory June 10, 2020 Nanoform Finland Oyj:n listautumisannin lisäosakeoption toteuttaminen ja vakauttamisajan päättäminen
Regulatory June 10, 2020 Utnyttjande av övertilldelningsoptionen i noteringen av Nanoform Finland Plc och avbrytande av stabiliseringsperioden
Regulatory June 9, 2020 De tio största aktieägarna i Nanoform Finland Plc efter genomförandet av noteringen
Regulatory June 9, 2020 Nanoform Finland Plc’s ten largest shareholders after the completion of the Initial Public Offering
Regulatory June 9, 2020 Nanoform Finland Oyj:n kymmenen suurinta osakkeenomistajaa listautumisannin päättymisen jälkeen
Regulatory June 3, 2020 Erbjudandet i samband med noteringen av Nanoform har kraftigt övertecknats och kommer att genomföras som planerat – handel i aktierna förväntas inledas imorgon
Regulatory June 3, 2020 The IPO of Nanoform has been considerably oversubscribed and the listing will be completed as planned – trading in the shares is expected to commence tomorrow
Regulatory June 3, 2020 Nanoformin listautumisanti on huomattavasti ylimerkitty ja listautuminen toteutetaan suunnitellusti – osakkeiden kaupankäynnin odotetaan alkavan huomenna
Regulatory June 2, 2020 The institutional offering of Nanoform has been considerably oversubscribed and therefore the subscription period has been closed
Regulatory June 2, 2020 Nanoformin Instituutioanti on huomattavasti ylimerkitty ja tämän takia merkintäaika on päätetty
Regulatory June 2, 2020 Det institutionella erbjudandet i Nanoform är kraftigt övertecknat och teckningsperioden har därmed avslutats
Regulatory June 1, 2020 Nanoformin Yleisöanti on huomattavasti ylimerkitty ja tämän takia merkintäaika on päätetty
Regulatory June 1, 2020 Erbjudandet i samband med noteringen av Nanoform är kraftigt övertecknat och teckningsperioden har därmed avslutats
Regulatory June 1, 2020 Public offering of Nanoform has been considerably oversubscribed and therefore the subscription period has been closed
Regulatory May 28, 2020 Nanoform Finland Plc har ansökt om upptagande till handel av dess aktier på Nasdaq First North Premier Growth Market Finland och Nasdaq First North Premier Growth Market Sweden
Regulatory May 28, 2020 Nanoform Finland Oyj on hakenut osakkeidensa listausta Nasdaq First North Premier Growth Market Finlandissa ja Nasdaq First North Premier Growth Market Swedenissä
Regulatory May 28, 2020 Nanoform Finland Plc has applied for its shares to be listed on Nasdaq First North Premier Growth Market Finland and Nasdaq First North Premier Growth Market Sweden
Regulatory May 25, 2020 Nanoform offentliggör en fast teckningskurs och publicerar ett prospekt för den planerade parallellnoteringen av dess aktier på Nasdaq First North Premier Growth Market i Finland & Sverige
Regulatory May 25, 2020 Nanoform julkistaa suunnitellun listautumisantinsa kiinteän merkintähinnan sekä esitteen liittyen kaksoislistautumiseensa Nasdaq First North Premier Growth Market -markkinapaikoille Suomessa ja Ruotsissa
Regulatory May 25, 2020 Nanoform announces a fixed subscription price and publishes a prospectus for its contemplated IPO and dual listing of its shares on Nasdaq First North Premier Growth Markets in Finland & Sweden
Regulatory May 11, 2020 Nanoform intends to launch an initial public offering and dual listing on Nasdaq First North Premier Growth Markets in Finland & Sweden
Regulatory May 11, 2020 Nanoform avser att genomföra ett erbjudande och att parallellnoteras på Nasdaq First North Premier Growth Market i Finland & Sverige
Regulatory May 11, 2020 Nanoform harkitsee listautumisantia ja kaksoislistautumista Nasdaq First North Premier Growth Market Finland ja Sweden -markkinapaikoille
Non Regulatory July 10, 2019 Nanoform appoints Director of Investor Relations following international growth
Non Regulatory May 28, 2019 Nanoform accelerates growth with Director of Project Management appointment
Non Regulatory April 29, 2019 Nanoform strengthens GMP capabilities with Head of Manufacturing appointment
Non Regulatory January 14, 2019 Nanoform set to boost world-class nanonization services with appointment of Chief Technology Officer
Non Regulatory January 7, 2019 Nanoform significantly strengthens commercial organisation with Chief of Business Operations appointment
Non Regulatory December 10, 2018 Nanoform continues rapid expansion with construction of GMP manufacturing plant
Non Regulatory October 29, 2018 Nanoform set to globalize its technology with appointment of a Chief Commercial Officer
Non Regulatory September 19, 2018 Nanoform set to transform drug development through €7 million investment in patented nanoparticle technology
